Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors.

In conclusion, the BsAbs-LsbMDDs preserved the physical properties of the LsbMDDs and actively targeted tumors with a drug cargo to enhance drug accumulation in tumors leading to greater antitumor activity against antigen-positive tumors. PMID: 29718725 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29718725?dopt=Abstract

Source: Drug Delivery - May 3, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research